• Publications
  • Influence
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year, but it cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement. Expand
Cost of disorders of the brain in Europe.
The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
A review of the available evidence with respect to the propensity of the SGAs and the newly approved antipsychotics to elevate PRL levels shows that although HPRL usually is defined as a sustained level of PRL above the laboratory upper limit of normal, limit values show some degree of variability in clinical reports, making the interpretation of data across studies difficult. Expand
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
Rates of MetS at the first episode of schizophrenia today are not different from those of patients 15 to 20 years ago, counters the notion that the high rates of metabolic abnormalities in patients with schizophrenia currently reported are mainly due to lifestyle changes over time in the general population. Expand
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
  • J. Peuskens
  • Psychology, Medicine
  • The British journal of psychiatry : the journal…
  • 1 June 1995
Risperidone is an effective antipsychotic for the treatment of chronic schizophrenia; doses of 4 and 8 mg seem to be optimal and have a lower incidence of side-effects than haloperidol. Expand
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
Treatment with antipsychotic medication is associated with moderate improvement in the cognitive test performance of patients who have schizophreniform disorder or who are in their first episode of schizophrenia. Expand
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.
Assessment of the presence and monitoring of metabolic abnormalities and its associated risks should be part of the clinical management of patients with bipolar disorder. Expand
Standardized remission criteria in schizophrenia
  • J. Os, T. Burns, +8 authors J. Kane
  • Psychology, Medicine
  • Acta psychiatrica Scandinavica
  • 1 February 2006
Objective:  Recent work has focussed on schizophrenia as a ‘deficit’ state but little attention has been paid to defining illness plasticity in terms of symptomatic remission.
Randomized comparison of ultra-brief bifrontal and unilateral electroconvulsive therapy for major depression: cognitive side-effects.
Ulabrief pulse ECT, used either in combination with a UL electrode position and a stimulus of 6 times ST, or a BF electrode position with a stimuli of 1.5 timesST, are effective antidepressant techniques, that do not have a deleterious effect on cognitive function. Expand
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia, and both treatments were equally effective against positive symptoms on the PANSS positive syndrome subscale. Expand